Skin: small trials, real but modest effects
Cosmetic endpoints — hydration, elasticity, wrinkle depth by imaging — are relatively easy to measure and cheap to study, so skin has more human data than most peptide areas. Two caveats apply to almost all of it: trials are short (8–16 weeks) and small (often under 100 participants), and most are funded by the company selling the ingredient. That does not make the results wrong, but it does mean we grade skin evidence no higher than promising until independent replication exists.
- Oral collagen peptides: several randomised placebo-controlled trials and pooled analyses report statistically significant improvements in skin hydration and elasticity. Effects are modest and the clinical meaningfulness of a few percent change in elastometry is debated.
- Topical GHK-Cu: small trials of copper peptide creams report improvements in photoaged skin. Formulations, concentrations and comparators vary widely, and independent replication is thin.
Hair: mostly animal and cell data
GHK-Cu is often marketed for hair growth. The supporting studies are largely in-vitro (dermal papilla cells) and animal, plus mechanistic reasoning by analogy to minoxidil. We are not aware of an adequately powered randomised human trial of a copper peptide for hair loss with a validated hair-count endpoint. Until one exists this claim stays preclinical on the GHK-Cu profile.
Comparison to approved options
For hair loss, minoxidil and finasteride have FDA approval and decades of trial data. For photoaging, topical retinoids are the evidence benchmark. Peptide claims should be read against those benchmarks, not against "doing nothing".